Novel Insulin Analog APT3598

—

●   APT3598 controls glucose better than Novo Nordisk’s Insulin Icodec in Sprague-Dawley rats, more consistently and for a longer time.

●   APT3598 has high potential for a pharmacologically better once-weekly injection drug as compared to Insulin Icodec.

●   Insulin Icodec was recently approved as a once-a-week injection in the EU and China but not in the USA.

●   The global 2023 sales of commercially approved once-daily insulin Degludec and insulin Glargine were $815 million and >$2 billion, respectively.

●   The global insulin market is >$40 billion and still growing with the increasing diabetes population.

In Sprague-Dawley rats, 175 nmol/rat APT3598 lowers glucose levels by ~50% within 48 hours, which is better compared to 175 nmol/rat Degludec and Icodec.

Contact: Simrat Singh, COO simrat.singh@ampeptec.com